Status:
COMPLETED
Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Scios, Inc.
Conditions:
Kidney Diseases
Congestive Heart Failure
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Patients hospitalized for treatment of decompensated heart failure (CHF) are at risk for prolonged length of stay (LOS) and frequent readmissions. Renal dysfunction and diuretic resistance contribute ...
Detailed Description
Hypothesis: The objective of this clinical practice protocol is to determine whether use of BNP in addition to standard therapy, will preserve renal function and facilitate diuresis in patients with ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of class III-IV CHF requiring hospitalization for treatment of CHF.
- Mild - moderate renal insufficiency (20\< Creatinine Clearance \< 60 ml/min as calculated by the Cockcroft-Gault formula)
- Systolic BP \> 90
- Stable cardiac rhythm
- Unlikely to require cardiac catheterization
Exclusion
- Inability to give informed consent
- New onset atrial fibrillation with rapid ventricular response (HR \>110 bpm)
- Active ischemia
- Known or suspected stenotic valve disease
- Acute clinical need for intravenous vasodilator (including BNP) therapy (Severely symptomatic despite rest, oxygen, initial standard therapy)
- Primary reason for admission other than treatment of decompensated CHF (rhythm, device, other medical problem)
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2008
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00170183
Start Date
March 1 2003
End Date
July 1 2008
Last Update
November 16 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905